Australia markets closed

Immunovant, Inc. (IMVT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
7.97-0.02 (-0.25%)
At close: 04:00PM EST
7.97 0.00 (0.00%)
After hours: 05:39PM EST
Full screen
Trade prices are not sourced from all markets
Previous close7.99
Open7.97
Bid0.00 x 900
Ask0.00 x 2200
Day's range7.76 - 8.13
52-week range6.68 - 53.61
Volume371,625
Avg. volume521,641
Market cap916.55M
Beta (5Y monthly)0.73
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Immunovant to Present at the Stifel 2021 Virtual Healthcare Conference

    NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will provide a corporate overview at the Stifel 2021 Virtual Healthcare Conference, taking place November 15-17, 2021. Stifel 2021 Virtual Healthcare Conference Presentation Date:Wednesday, November 17th, 2021Time: 2:00pm Eastern TimeWebcast:

  • GlobeNewswire

    Immunovant Reports Financial Results for the Quarter Ended September 30, 2021

    Company Ended the Quarter With Cash of Approximately $559 MillionNEW YORK, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today reported financial results for its fiscal first quarter ended September 30, 2021. Immunovant ended the quarter with approximately $559 million in cash. Financial Highlights for Fiscal Second Quarter Ended September 30, 2021: R&D Expenses:

  • GlobeNewswire

    Immunovant to Participate in Roivant R&D Day 2021

    NEW YORK, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in a fireside chat during Roivant R&D Day 2021 on Tuesday, September 28, 2021 at 4:00 p.m. ET. A live webcast of the event can be accessed at www.tinyurl.com/roivant. A replay of the event will be archived under the ‘Events’